Shareholders approve Zymeworks merger; closing expected Sept 23, 2026

Theravance Biopharma, Inc.

Merger Proposal approved: 40,993,370 for, 8,671 against, 84,733 abstentions (>2/3 required).
Advisory merger-related compensation proposal also approved (40,587,829 for, 470,381 against).
Merger expected to close on or about Sept 23, 2026; Theravance to become wholly owned subsidiary of Zymeworks.
CVR Agreement contingent consideration remains subject to future payment conditions.
Quorum of 79.14% (41,086,774 shares) present; adjournment proposal not needed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.